Infensa’s lead drug was shown to protect hearts from injury after heart attack and to preserve the integrity of donor hearts destined for transplantation in apaper published in Circulation, the world’s top-ranked cardio-vascular journal. Worldwide press coverage of this breakthrough research, which has reached almost 1 billion people, places it in the top 20 of 18,352 papers published by the journal since its inception in 1950.